OSE Pharma is a biotech company that designs and develops cancer immunotherapy treatments using its Memopi® technology, through “neo-epitopes” (small synthetic peptides chemically modified to increase the binding the HLA A2 or TCR receptors) which triggers a cytotoxic T-cell response and leads the immune system to destroy cancer cells. More than 10,000 epitopes were selected. Its lead product Tedopi® (OSE-2101) combines 10 optimized “neo-epitopes” simultaneously acting against 5 tumor-associated antigens (TAAs). These 5 antigens have been selected because they are a factor of poor prognosis in several types of cancers. The 10 optimized “neo-epitopes” have been selected and modified to enhance their binding to HLA-A2 and TCR receptors, and trigger a stronger T-cell response. These strong cytotoxic T-cell responses lead the immune system to destroy tumor cells expressing HLA-A2 antigens and one of the targeted tumor antigens (TCR).
Tel: +33 (0) 1 43 29 78 57
Fax: +33 (0) 9 70 06 80 94
email: info@osepharma.com
Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented…
Olivier Laureau, President of the Servier Group, discusses how Servier´s economic model is based on considerable investments in R&D to provide for a better future and on a strong international…
Stéphane Thiroloix, CEO of the independent and family owned Mayoly Spindler, reveals how their vision is to become a reference company internationally in the field of gastroenterology and dermocosmetics; how…
Jean-Charles Foddis, executive director of Aderly, Lyon’s main investment agency, discusses the city’s history of economic development while highlighting its main strengths and challenges for the future in life sciences.…
Amatsigroup, a Contract Development and Manufacturing Organization (CDMO), provides services throughout both preclinical and clinical phases. Leading over 200 highly qualified employees with a portfolio of over 300 clients, President…
Providing an all-in-one venue for major corporate conference, seminar, or gala events, Disney Business Solutions at Disneyland Paris provides customized services to meet all clients’ needs. Director Nicolas Dupeux shares…
André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution;…
Serving as the leader of two companies – Platine, a CRO, and Indicia, a CMO – Stephane Legastelois, in his own words, challenges himself by wearing two different hats. Offering…
Laurence Comte-Arassus, president of Medtronic France, reveals how after the global acquisition of Covidien in January 2015, France is now their second largest subsidiary in the EMEA region; how Medtronic´s…
Nicolas Bardonnet, general manager of Promega France, reveals how France hosts both their European application laboratory and European training centre, offering a wide range of courses in molecular biology, cell…
The October 2015 merger between Houston, TX-based Cyberonics and Milan, Italy-based Sorin has led the creation of LivaNova, a medical device manufacturer active in the fields of cardiac surgery, neuromodulation…
Philippe Chêne, President of Winncare, reveals how he has led the company to be a force to be reckoned with as an advocate of preventative healthcare. An exemplary case of…
Christophe Lala, general manager of Western Europe at GE Healthcare, reveals how today the challenge is to ensure that all patients in France have access to the same medical pathway;…
See our Cookie Privacy Policy Here
